Otsuka (OTCMKTS:OTSKY) Reaches New 1-Year High – Time to Buy?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $30.7940 and last traded at $30.7940, with a volume of 1441 shares. The stock had previously closed at $30.11.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on OTSKY shares. Zacks Research cut shares of Otsuka from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Morgan Stanley upgraded Otsuka to an “overweight” rating in a report on Friday, January 23rd. Finally, UBS Group upgraded Otsuka to a “hold” rating in a report on Tuesday, January 27th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Otsuka Stock Up 2.8%

The firm has a fifty day moving average price of $29.37 and a two-hundred day moving average price of $27.87.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.